LumiMeds
LumiMeds offers clinician-reviewed compounded semaglutide, tirzepatide and NAD+ injections. Clear product descriptions sit alongside strict commitment terms that need resolving before enrollment.
Review by Leah Garner, clinical-evidence editor · Updated October 2026
The short version
The product pages explain routes and clinical review, but the financial commitment is a material drawback. Establish the assigned practice, selected plan term and ability to stop before treating a monthly headline as flexible care.
Disclosure: This Peptide is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
FDA warning letter on record: Letter 716510 · September 2025
LumiMeds is a patient-management platform working with independent clinicians and dispensing pharmacies. Its current product pages identify compounded semaglutide and tirzepatide as subcutaneous injections. A separate NAD+ page also identifies an injectable compounded preparation. These are prescription services, rather than direct sales of an approved generic drug. The website says payment does not guarantee prescribing. That is an important boundary, particularly when promotional pages emphasize quick eligibility and simple delivery. Ask the clinician to explain why the specific preparation is proposed and how treatment will be assessed after the initial supply.
What LumiMeds prescribes, by goal
Weight
- SemaglutideFDA-approved
Listed by the seller; no price we hold.
- TirzepatideFDA-approved
Listed by the seller; no price we hold.
The product descriptions distinguish compounded semaglutide from compounded tirzepatide and identify their injection route. Both pages acknowledge that the finished preparations are not FDA-approved. Ask what patient-specific need supports the proposed compounded product and what approved alternatives are available. Product-site testimonials are not clinical evidence that the same result will occur for another person.
Longevity
- NAD+Compounding conditions apply
Listed by the seller; no price we hold.
The NAD+ page promotes energy, recovery and healthy aging through a compounded injection. It names Olympia as a pharmacy source and describes clinician check-ins. Those details do not establish that the preparation reverses aging or produces the advertised benefits for a particular patient. Ask which measurable outcome will justify continuing, and what findings would lead the clinician to stop.
Who prescribes
A licensed clinician
The platform’s legal operator is Luminate Ventures LLC doing business as LumiMeds. Its terms identify Telegra MD LLC in connection with medical services. That separates the administrative platform from the clinical relationship, but does not identify the clinician assigned to each patient. Obtain the name and practice of the person reviewing the intake and responsible for follow-up. The NAD+ page names Olympia as a pharmacy source, while the GLP-1 pages describe a state-licensed compounding pharmacy without a specific name. Ask who will actually dispense the selected medication and whether that assignment can change between orders.
The NAD+ plan explicitly includes ongoing clinician check-ins. The advertised process starts with health-history review by a licensed provider, followed by pharmacy fulfillment if treatment is prescribed. The product FAQs describe later review of progress and possible plan adjustments. This provides a basis for follow-up, without establishing a universal live-visit schedule. Ask how to arrange a conversation when a symptom cannot be handled adequately through messages. Administrative support hours and a prescription review are different services. A patient also needs to know who arranges outside examination or testing if online care is insufficient. The written care plan should make that responsibility clear before a long financial commitment begins.
Are labs required?
Not mentioned
No universal public laboratory protocol or complete testing charge was established across these treatment pages. A clinical-history review is described, but the patient should ask what baseline information is needed for the chosen preparation. Confirm whether outside results are accepted, who interprets them and how follow-up testing is arranged. Product quality controls at a pharmacy are not a substitute for assessing the patient’s health. A person considering ongoing treatment should understand what happens if the clinician requests an in-person examination or decides the online program is no longer appropriate.
Ready to start with LumiMeds?
Prices and plans are set on the seller's own site.
What it claims, and what it cites
LumiMeds emphasizes provider oversight, convenient delivery and personalized care. FDA issued a warning letter dated September 9, 2025 concerning the company’s compounded semaglutide and tirzepatide advertising. It challenged claims implying the same clinical benefits as approved products. That is a dated advertising record, rather than proof about a present patient’s vial or outcome. The current pages acknowledge that compounded preparations are not FDA-approved. Keep that distinction when evaluating broad statements about a known active ingredient’s evidence. The NAD+ page also reuses weight-loss testimonials; those statements cannot demonstrate that an NAD+ preparation produced those weight changes.
How it bills
Product headlines list semaglutide at $89 per month, tirzepatide at $125 per month and NAD+ starting at $133 per month. They also advertise multiple plan lengths without establishing which duration produces each displayed figure. The membership terms require payment of the full selected term, even when collected in installments. They broadly prohibit cancellation and refunds once a term starts, then describe limited refunds with a $100 cancellation deduction. Prescription denial is separately described as eligible for a full refund. Obtain the exact applicable terms in writing; a monthly installment is not necessarily a freely cancelable monthly service.
For and against
- For: Ingredients and injection routes identified
- For: Compounded status disclosed on product pages
- For: NAD+ page names its pharmacy source
- For: Clinical progress reviews described
- Against: Full plan obligation can survive installment payments
- Against: Cancellation and refund clauses need reconciliation
- Against: Ordinary one-month headline amount is not established
- Against: FDA previously challenged compounded-drug advertising
The evidence behind what it sells
Right for
Someone who understands the complete financial commitment and will verify the treating clinician, dispenser and follow-up plan before enrolling.
Look elsewhere if
A patient seeking a flexible trial month or assuming a monthly payment display means the remaining commitment can be canceled.
Other sellers for weight
Velvet Rx
Also prescribes Semaglutide, Tirzepatide.
Blue Sky MD
Also prescribes Semaglutide, Tirzepatide.
AJ Peptide
Also prescribes Semaglutide, Tirzepatide.
LumiMeds
Frequently asked questions
- Does a monthly payment mean the plan can stop after a month?
- Not necessarily. The terms describe a fixed-term obligation that remains payable even when collected in installments.
- Is the NAD+ pharmacy named?
- The NAD+ product page names Olympia. Confirm the actual dispenser for the order; the GLP-1 pages do not establish the same pharmacy assignment.
- Is payment a guarantee of receiving medication?
- No. The product pages say prescribing depends on the clinician’s review, with prescription-denial refund provisions stated separately.
- Do weight-loss testimonials establish NAD+ effectiveness?
- No. Weight-loss accounts do not establish that a particular NAD+ injection caused the reported result.
Sources
- Semaglutide preparation and route
- Tirzepatide offer and clinical review
- NAD+ injection and named pharmacy source
- Commitment, cancellation and refund provisions
- Platform company and clinical service entities
- Clinical program questions
- FDA advertising warning dated September 9, 2025
See what LumiMeds prescribes today
LumiMeds sets its own prices, plans and the states it serves. Check them before you start.